Sponsors Rein In Clinical Trial Violation Rate, But Monitoring Is Problematic
This article was originally published in The Gray Sheet
Executive Summary
Despite improvements in sponsors' compliance with clinical trial regulations last year, trial monitoring continues to be an issue, according to CDRH
You may also be interested in...
FDA Urges Centralized Clinical Trial Monitoring Over Frequent On-Site Visits – Guidance
Clinical trial sponsors should make greater use of off-site centralized monitoring, in place of frequent on-site visits, to ensure the quality of their trials, FDA emphasizes in new draft guidance.
FDA Urges Centralized Clinical Trial Monitoring Over Frequent On-Site Visits – Guidance
Clinical trial sponsors should make greater use of off-site centralized monitoring, in place of frequent on-site visits, to ensure the quality of their trials, FDA emphasizes in new draft guidance.
Device Research Compliance Is On Positive Trend – FDA Official
Device companies and other organizations involved in device research have made significant improvements in recent years in complying with FDA research regulations, an agency official said last week.